2.01

9.24% 0.17

Black Diamond Therapeutics Inc (BDTX)

Overview News Price History Option Chain Financials Discussions Forecast

Black Diamond Therapeutics Inc stock is traded at $2.01, with a volume of 1.57M. It is up +9.24% in the last 24 hours and down -7.80% over the past month. Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.

Previous Close:

$1.84

Open:

$1.83

24h Volume:

1.57M

Relative Volume:

0.98

Market Cap:

$115.18M

Revenue:

$70.00M

Net Income/Loss:

$-43.21M

P/E Ratio:

-2.6521

EPS:

-0.7579

Net Cash Flow:

$-34.03M

1W Performance:

+18.24%

1M Performance:

-7.80%

6M Performance:

-19.28%

1Y Performance:

-22.69%

1-Day Range:

$1.83

$2.035

1-Week Range:

$1.68

$2.035

52-Week Range:

$1.60

$4.94

Black Diamond Therapeutics Inc Stock (BDTX) Company Profile

Name

Black Diamond Therapeutics Inc

Sector

Healthcare (1098)

Industry

Biotechnology (615)

Phone

617-417-5868

Address

245 FIRST STREET, 18TH FLOOR, CAMBRIDGE, MA

Employee

Twitter

Next Earnings Date

2026-08-06

Latest SEC Filings

BDTX's Discussions on Twitter

Compare BDTX vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BDTX Black Diamond Therapeutics Inc	2.01	106.01M	70.00M	-43.21M	-34.03M	-0.7579
VRTX Vertex Pharmaceuticals Inc	528.04	126.07B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	654.27	65.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	939.68	57.70B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	312.78	40.19B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	189.24	39.82B	742.00K	-1.37B	-1.07B	-7.0731

Black Diamond Therapeutics Inc Stock (BDTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-03-25	Downgrade	Guggenheim	Buy → Neutral
Nov-18-25	Resumed	Piper Sandler	Overweight
Oct-16-25	Resumed	Stifel	Buy
Sep-04-25	Initiated	Guggenheim	Buy
Jul-01-25	Resumed	Raymond James	Outperform
Jul-31-24	Initiated	Raymond James	Outperform
Jul-14-23	Initiated	Piper Sandler	Overweight
Jun-30-23	Upgrade	Stifel	Hold → Buy
Jun-28-23	Upgrade	H.C. Wainwright	Neutral → Buy
Jun-27-23	Upgrade	Wedbush	Neutral → Outperform
Mar-29-22	Downgrade	Wedbush	Outperform → Neutral
Mar-22-22	Downgrade	H.C. Wainwright	Buy → Neutral
Sep-30-21	Initiated	Stifel	Hold
Jan-07-21	Initiated	Wedbush	Outperform
Nov-24-20	Initiated	Berenberg	Buy
May-04-20	Initiated	H.C. Wainwright	Buy
Feb-24-20	Initiated	Canaccord Genuity	Buy
Feb-24-20	Initiated	Cowen	Outperform
Feb-24-20	Initiated	JP Morgan	Overweight
Feb-24-20	Initiated	Jefferies	Buy

View All

Black Diamond Therapeutics Inc Stock (BDTX) Latest News

Jun 30, 2026

Black Diamond Therapeutics touts Silevertinib lung cancer data, eyes FDA path - MSN

Jun 30, 2026

Black Diamond Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Raman Prakash - Moomoo

Jun 30, 2026

Jun 29, 2026

Black Diamond Therapeutics 2026 Annual Stockholder Meeting Results and Voting Outcomes - Minichart

Jun 29, 2026

Form 4 Black Diamond Therapeutics Inc For: 29 June By Investing.com - Investing.com Nigeria

Jun 29, 2026

[Form 4] Black Diamond Therapeutics, Inc. Insider Trading Activity - Stock Titan

Jun 29, 2026

Black Diamond (BDTX) director awarded 40,000 stock options at $1.71 - Stock Titan

Jun 29, 2026

Black Diamond Therapeutics (BDTX) director awarded 40,000 stock options at $1.71 - Stock Titan

Jun 29, 2026

Director Garry Menzel granted 40,000 BDTX stock options at $1.71 strike - Stock Titan

Jun 29, 2026

Black Diamond (NASDAQ: BDTX) director receives 40,000 stock options at $1.71 - Stock Titan

Jun 29, 2026

Black Diamond Therapeutics (BDTX) awards 40,000-share option grant - Stock Titan

Jun 29, 2026

Black Diamond Therapeutics (BDTX) 2026 meeting backs directors, auditor and annual say-on-pay - Stock Titan

Jun 29, 2026

Black Diamond Therapeutics, Inc.(NasdaqGS: BDTX) added to Russell 2000 Index - marketscreener.com

Jun 29, 2026

Black Diamond Therapeutics, Inc.(NasdaqGS:BDTX) added to Russell 2000 Value Benchmark - marketscreener.com

Jun 29, 2026

Black Diamond Therapeutics, Inc.(NasdaqGS: BDTX) added to Russell 3000E Index - marketscreener.com

Jun 29, 2026

Enterprise value to EBITDA forward of Black Diamond Therapeutics, Inc. – NASDAQ:BDTX - TradingView

Jun 29, 2026

Jun 28, 2026

Black Diamond Therapeutics, Inc.(NasdaqGS:BDTX) added to Russell 3000 Value Benchmark - marketscreener.com

Jun 28, 2026

Jun 26, 2026

Black Diamond Therapeutics (BDTX) AGM 2026 Summary - Quartr

Jun 26, 2026

Price to sales forward of Black Diamond Therapeutics, Inc. – NASDAQ:BDTX - TradingView

Jun 26, 2026

Price to book forward of Black Diamond Therapeutics, Inc. – BOATS:BDTX - TradingView

Jun 26, 2026

Black Diamond Therapeutics, Inc. Actuals & Estimates (NASDAQ:BDTX) - TradingView

Jun 26, 2026

Jun 25, 2026

Enterprise value to EBIT forward of Black Diamond Therapeutics, Inc. – NASDAQ:BDTX - TradingView

Jun 25, 2026

Price to earnings forward of Black Diamond Therapeutics, Inc. – BOATS:BDTX - TradingView

Jun 25, 2026

Price to sales forward of Black Diamond Therapeutics, Inc. – BOATS:BDTX - TradingView

Jun 25, 2026

Enterprise value to revenue forward of Black Diamond Therapeutics, Inc. – BOATS:BDTX - TradingView

Jun 25, 2026

BDTX shares gain 11% in a week: Here's what you should know - MSN

Jun 25, 2026

BDTX Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026

Jun 23, 2026